Abbasi Saed, Matsui-Masai Miki, Yasui Fumihiko, Hayashi Akimasa, Tockary Theofilus A, Mochida Yuki, Akinaga Shiro, Kohara Michinori, Kataoka Kazunori, Uchida Satoshi
Innovation Center of NanoMedicine (iCONM), Kawasaki Institute of Industrial Promotion, 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki 210-0821, Japan.
Department of Research, NANO MRNA Co., Ltd., 3-25-14 Tonomachi, Kawasaki-ku, Kawasaki 210-0821, Japan.
Mol Ther. 2024 May 1;32(5):1266-1283. doi: 10.1016/j.ymthe.2024.03.022. Epub 2024 Apr 2.
Carrier-free naked mRNA vaccines may reduce the reactogenicity associated with delivery carriers; however, their effectiveness against infectious diseases has been suboptimal. To boost efficacy, we targeted the skin layer rich in antigen-presenting cells (APCs) and utilized a jet injector. The jet injection efficiently introduced naked mRNA into skin cells, including APCs in mice. Further analyses indicated that APCs, after taking up antigen mRNA in the skin, migrated to the lymph nodes (LNs) for antigen presentation. Additionally, the jet injection provoked localized lymphocyte infiltration in the skin, serving as a physical adjuvant for vaccination. Without a delivery carrier, our approach confined mRNA distribution to the injection site, preventing systemic mRNA leakage and associated systemic proinflammatory reactions. In mouse vaccination, the naked mRNA jet injection elicited robust antigen-specific antibody production over 6 months, along with germinal center formation in LNs and the induction of both CD4- and CD8-positive T cells. By targeting the SARS-CoV-2 spike protein, this approach provided protection against viral challenge. Furthermore, our approach generated neutralizing antibodies against SARS-CoV-2 in non-human primates at levels comparable to those observed in mice. In conclusion, our approach offers a safe and effective option for mRNA vaccines targeting infectious diseases.
无载体裸mRNA疫苗可能会降低与递送载体相关的反应原性;然而,它们对传染病的有效性一直不太理想。为了提高疗效,我们针对富含抗原呈递细胞(APC)的皮肤层,并使用了喷射注射器。喷射注射有效地将裸mRNA引入皮肤细胞,包括小鼠体内的APC。进一步分析表明,APC在皮肤中摄取抗原mRNA后,迁移至淋巴结(LN)进行抗原呈递。此外,喷射注射引发了皮肤局部淋巴细胞浸润,起到了疫苗接种的物理佐剂作用。在没有递送载体的情况下,我们的方法将mRNA分布限制在注射部位,防止全身mRNA泄漏及相关的全身促炎反应。在小鼠疫苗接种中,裸mRNA喷射注射在6个月内引发了强烈的抗原特异性抗体产生,同时在LN中形成生发中心,并诱导CD4和CD8阳性T细胞。通过靶向严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白,这种方法提供了针对病毒攻击的保护。此外,我们的方法在非人类灵长类动物中产生了与在小鼠中观察到的水平相当的针对SARS-CoV-2的中和抗体。总之,我们的方法为针对传染病的mRNA疫苗提供了一种安全有效的选择。